A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.

@article{Gmez2017API,
  title={A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.},
  author={David G{\'o}mez and Helen Razmjou and A. Tipton Donovan and Vikas B Bansal and Jeffrey D Gollish and John J Murnaghan},
  journal={The Journal of arthroplasty},
  year={2017},
  volume={32 3},
  pages={958-964}
}
BACKGROUND Multiple randomized controlled trials have documented the effectiveness of rivaroxaban in the prevention of venous thromboembolism up to 1-month following total joint arthroplasty. However, the effectiveness and safety of rivaroxaban in the real-world setting, outside of the strict protocols used by randomized clinical trials, are unknown… CONTINUE READING